On March 6, 2026, the Food and Drug Administration (“FDA” or “the Agency”) issued a draft guidance, “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.” The draft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results